Halozyme Therapeutics, Inc. (HALO) Up 15.6% — Should I Seize This Momentum?
Halozyme Therapeutics, Inc. (HALO) delivered one of the more decisive single-session moves in the Health Care space on Friday, surging 15.57% and adding $13.35 to close at $99.11 on the NASDAQ. The catalyst was unmistakable: record second-quarter results released the prior evening ignited broad-based buying that carried the stock through its previous 52-week high of $86.00—set just one day earlier on August 6—and pushed HALO into entirely new territory above the $99 mark.
Trading volume came in at approximately 3.6 million shares, more than double the 90-day average of roughly 1.7 million. That kind of turnover on a breakout day is notable—it signals genuine conviction behind the move rather than a thin-volume drift higher. The combination of a fresh all-time high and significantly elevated participation makes this session difficult to dismiss as noise.
Why Halozyme Therapeutics, Inc. Price is Moving Higher
The catalyst driving HALO sharply higher is straightforward: a record-setting Q2 2026 earnings report that beat estimates by a wide margin on every key metric and prompted an aggressive raise to full-year guidance. Adjusted EPS came in at $2.28 versus the $1.82 consensus estimate—a $0.46, or 25.5%, beat. Revenue of $481.0 million demolished the $404.3 million expected figure, growing 47.7% year over year from $325.7 million in the prior-year quarter. Adjusted EBITDA rose 46% to $328.8 million, delivering a 68.4% margin, while net income climbed 39% to $229.9 million and GAAP diluted EPS improved to $1.90 from $1.33 a year ago. Those are not incremental beats—they represent a step-change in the company's financial profile that investors couldn't afford to underweight.
The engine behind those results is HALO's ENHANZE drug delivery platform, which continues to generate royalty revenue at an accelerating pace. Royalty revenue rose 50% to $307.7 million in Q2, fueled by continued adoption of ENHANZE-based products including argenx's VYVGART Hytrulo and Janssen's DARZALEX SC—two of the fastest-growing biologics in their respective categories. Management didn't just report strong results; it raised 2026 guidance across every major measure, lifting the revenue range to $1.835 billion–$1.910 billion from $1.710 billion–$1.810 billion, royalty revenue to $1.220 billion–$1.245 billion from $1.130 billion–$1.170 billion, and non-GAAP EPS to $8.65–$9.00 from $7.75–$8.25. Adding further depth to the pipeline story, Halozyme disclosed that it had signed five new ENHANZE or Hypercon collaborations through July alone, including partnerships with Vertex, Oruka, GSK, and Incyte—a development that materially expands the long-term royalty runway.
Analyst reaction amplified the momentum and helped sustain buying throughout the session. Leerink upgraded HALO to Outperform and set a $110 price target. HC Wainwright raised its target from $95 to $115 while maintaining a Buy rating. Even Wells Fargo, which retained its Equal Weight stance, lifted its target from $75 to $95. That kind of coordinated upward revision across multiple firms—spanning outright upgrades and target increases alike—reinforces the view that the investment community is recalibrating its expectations for HALO's earnings power, not just reacting to a single good quarter.
What is the Halozyme Therapeutics, Inc. Rating - Should I Buy?
Weiss Ratings assigns HALO a B rating. Current recommendation is Buy. That assessment reflects a business that scores at the top of the scale across three critical dimensions—growth, efficiency, and balance sheet health—making Halozyme one of the stronger Buy-rated names in the Health Care sector.
The numbers behind those ratings are genuinely impressive. Revenue growth of 42.23% earns the Excellent Growth Index—a figure that speaks to the compounding effect of the ENHANZE royalty model as partner products gain commercial traction across oncology and immunology. The profit margin of 23.12% reinforces that this growth is translating into real earnings rather than being consumed by cost inflation or pipeline spending. Most striking is the ROE of 99.40%, which anchors the Excellent Efficiency Index—an exceptional return for a biopharmaceutical company whose asset-light royalty structure allows it to generate outsized earnings without the capital-intensive manufacturing footprint that weighs on traditional drug makers. The Excellent Solvency Index rounds out the picture, indicating that Halozyme is managing its balance sheet with discipline appropriate to its stage of development.
The Fair Total Return Index and Fair Volatility Index are the counterweights worth acknowledging. The volatility reading is consistent with what investors should expect from a single-platform biotech—HALO's fortunes remain tightly linked to the clinical and commercial success of its partners' ENHANZE-enabled products, and any disruption there could move the stock sharply in either direction. The forward P/E of 30.89 is not expensive in absolute terms for a company growing revenue at 42% with near-70% EBITDA margins, but it does embed meaningful execution expectations that management will need to continue meeting.
Within the Health Care sector, Halozyme is on equal footing with Eli Lilly and Company (LLY, B), Johnson & Johnson (JNJ, B), and Amgen Inc. (AMGN, B)—a peer group that includes some of the most widely held names in the sector. It ranks ahead of AbbVie Inc. (ABBV, B-) and Gilead Sciences, Inc. (GILD, B-), a relative positioning that reflects HALO's superior growth trajectory and efficiency metrics compared to larger but slower-moving peers.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) is a Health Care company built around a proprietary drug delivery technology platform that has quietly become one of the most commercially valuable tools in the biopharmaceutical industry. Unlike traditional drug developers, Halozyme does not derive its primary revenue from selling its own branded medicines—instead, it licenses its ENHANZE technology to leading pharmaceutical companies, enabling them to convert intravenous biologics into subcutaneous formulations that can be administered in minutes rather than hours. That model generates royalties on partner product sales, creating a recurring, scalable revenue stream with economics that look far more like a software licensing business than a typical biotech.
The ENHANZE platform works by leveraging recombinant human hyaluronidase enzyme (rHuPH20) to temporarily and locally increase permeability in the subcutaneous space, allowing large-molecule drugs to be delivered under the skin at volumes and speeds not previously possible. For patients, the practical impact is significant—moving from a two-hour infusion in a clinical setting to a five-minute injection at home materially improves convenience and adherence. For Halozyme's partners, subcutaneous reformulation can extend product lifecycles, create differentiation at the point of prescribing, and open new patient populations. That dual value proposition has attracted a partner roster that includes Janssen, argenx, Roche, Pfizer, AbbVie, and now Vertex, Oruka, GSK, and Incyte, among others.
Beyond ENHANZE, the company has been developing Hypercon, its next-generation high-volume subcutaneous delivery technology designed to handle larger doses than the existing platform—expanding the addressable partner landscape further. Halozyme's competitive advantage is rooted in its deep intellectual property position, its regulatory and manufacturing expertise in enabling subcutaneous biologics, and the long product lifecycle of approved ENHANZE-based medicines. As partner products like DARZALEX SC and VYVGART Hytrulo continue to gain commercial share in large indications, the royalty base compounds in a way that requires minimal incremental investment from Halozyme itself—a structural advantage that few peers can replicate.
Investor Outlook
Halozyme Therapeutics, Inc. carries a Weiss Rating of B (Buy), backed by record quarterly results, a substantial guidance raise, and a growing pipeline of new ENHANZE and Hypercon partnerships that extend the royalty revenue runway well into the next decade. Investors will want to monitor continued commercial uptake of key ENHANZE-enabled products, execution on the five new collaborations signed through July 2026, and whether forward guidance continues to move higher as partner launches progress. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--